title: Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
abstract: OBJECTIVE
  Theoretical concern exists that rapid luminal healing in Crohn's disease (CD) with therapies like infliximab increases the risk of intestinal stenosis, stricture, or obstruction (SSOs).
  
  
  METHODS
  Data were analyzed from the ongoing observational TREAT (the Crohn's Therapy, Resource, Evaluation, and Assessment Tool) Registry and ACCENT I (A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Long-Term Treatment Regimen) study. Investigators reported SSOs as adverse events or serious adverse events.
  
  
  RESULTS
  In TREAT, SSOs occurred at a significantly higher rate in patients treated with infliximab compared with patients who received other treatments only (1.95 events/100 patient-years vs 0.99 events/100 patient-years; p < 0.001). Using multivariable analyses, however, infliximab therapy was not associated with SSO development. CD severity at the time of event onset (hazard ratio (HR) = 2.35, 95% confidence internal (CI) 1.35-4.09); CD duration (HR = 1.02, 95% CI 1.00-1.04); ileal disease (HR = 1.56, 95% CI 1.04-2.36); and new corticosteroid use (HR = 2.85, 95% CI 1.23-6.57) were associated with SSOs. In ACCENT I, no increase in SSOs was reported in patients who received infliximab maintenance therapy compared with those who received episodic therapy, despite higher median cumulative infliximab exposure. Additionally, there was no increase in SSO development with rapid mucosal healing (healing at week 10).
  
  
  CONCLUSIONS
  Although unadjusted analyses suggested that patients who received infliximab were twice as likely to develop SSOs, multivariable analysis adjusting for other factors demonstrated that only disease duration, disease severity, ileal disease, and new corticosteroid use were significantly associated with SSO development.
authors.affiliation: Division of Gastroenterology, Department of Medicine, Hospital of The University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-4283, USA.
authors.forename: Gary R
authors.initials: GR
authors.lastname: Lichtenstein
authors.forename: Allan
authors.initials: A
authors.lastname: Olson
authors.forename: Suzanne
authors.initials: S
authors.lastname: Travers
authors.forename: Robert H
authors.initials: RH
authors.lastname: Diamond
authors.forename: Donny M
authors.initials: DM
authors.lastname: Chen
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Pritchard
authors.forename: Brian G
authors.initials: BG
authors.lastname: Feagan
authors.forename: Russell D
authors.initials: RD
authors.lastname: Cohen
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Salzberg
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Hanauer
authors.forename: William J
authors.initials: WJ
authors.lastname: Sandborn
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D003251:Constriction, Pathologic; D003424:Crohn Disease / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D000069285:Infliximab; D007415:Intestinal Obstruction / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011446:Prospective Studies
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab